XML 136 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Contract revenues, Anti-Abeta Antibody in AD - 2006 Agreement with Genentech (Details)
SFr in Thousands, $ in Millions
12 Months Ended 36 Months Ended 194 Months Ended
Dec. 31, 2022
CHF (SFr)
Dec. 31, 2021
CHF (SFr)
Dec. 31, 2020
CHF (SFr)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CHF (SFr)
payment
Dec. 31, 2022
USD ($)
payment
Dec. 31, 2022
USD ($)
Mar. 31, 2017
CHF (SFr)
Mar. 31, 2017
USD ($)
Contract revenues                  
Revenue from contracts with customers | SFr SFr 3,935 SFr 0 SFr 15,431            
Anti-Abeta Antibody in AD [Member] | 2006 Agreement with Genentech [Member]                  
Contract revenues                  
Period to provide notice of termination of agreement 3 months                
Cumulative payments received SFr 70,100       SFr 70,100   $ 65    
Milestone payment received         SFr 38,200 $ 40      
Up-front consideration received               SFr 31,600 $ 25
Number of milestone payments received | payment         3 3      
Revenue from contracts with customers | $       $ 0          
Collaborative agreement, upfront payments received         SFr 31,600 $ 25      
Collaborative agreement, Notice of contract termination period in case of material breach of contract 90 days                
Anti-Abeta Antibody in AD [Member] | 2006 Agreement with Genentech [Member] | Clinical milestones achieved prior to 1 January 2017                  
Contract revenues                  
Milestone payment received         38,200 $ 40      
Anti-Abeta Antibody in AD [Member] | 2006 Agreement with Genentech [Member] | Minimum                  
Contract revenues                  
Total potential collaboration agreement value SFr 317,000       317,000   340    
Total potential collaboration agreement value remaining SFr 256,400       SFr 256,400   $ 275